
In one of its first actions, the Biden administration rejoined the United States in the World Health Organization, reversing a policy of its predecessor. . . . → Read More: U.S. Rejoins WHO, Participates in Int’l Vaccine Project
|
|||||
![]() In one of its first actions, the Biden administration rejoined the United States in the World Health Organization, reversing a policy of its predecessor. . . . → Read More: U.S. Rejoins WHO, Participates in Int’l Vaccine Project ![]() A clinical trial shows long-term care residents and staff receiving a synthetic antibody treatment have a lower risk of getting symptomatic Covid-19 infections. . . . → Read More: Antibodies Prevent Covid-19 Symptoms in Long-Term Care ![]() A company applying Crispr gene-editing technology to treat inherited heart disease is raising $94 million in its second venture funding round. . . . → Read More: Crispr Heart Disease Biotech Raises $94M in New Funds ![]() A vaccine protecting against multiple Covid-19 viral variations is in development, with an early-stage clinical trial expected to begin soon. . . . → Read More: Multi-Variant Covid-19 Vaccine in the Works ![]() A study now underway is tracking long-term effects of Covid-19 infections using real-world data from electronic sources provided by patients. . . . → Read More: Registry Tracking Long-Term Covid-19 Impacts ![]() An engineering team demonstrated a small robotic device that fits on current surgical equipment to improve laser surgery inside the body. . . . → Read More: Micro-Robot Designed to Aid Internal Laser Surgery ![]() A biotechnology enterprise is licensing research from Stanford University on messenger RNA to produce proteins that rejuvenate cells damaged by aging. . . . → Read More: Biotech Licenses mRNA Technology for Aging ![]() The U.S. Department of Health and Human Services is buying up to 1.25 million more doses of Regeneron’s Covid-19 antibody therapy, for $2.63 billion. . . . → Read More: US Govt to Buy 1.25M Regeneron Covid-19 Therapies ![]() Global drug maker Boehringer Ingelheim is gaining access to an immunotherapy technology that targets usually hidden proteins to attack cancer cells. . . . → Read More: Drug Maker Gains Access to Hidden Protein Immunotherapies ![]() Moderna Inc., developer of a currently authorized Covid-19 vaccine, is expanding its vaccine pipeline to cover three more common infectious viral diseases. . . . → Read More: Moderna Developing Flu, HIV, Nipah Vaccines |
|||||
Copyright © 2021 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |